The AI-Mind project (grant agreement ID: 964220) is approaching completion, with its multi-centre data collection nearly finalised. This ambitious European research initiative has successfully established one of the most comprehensive longitudinal datasets focused on Mild Cognitive Impairment and dementia progression. The AI-Mind dataset now includes longitudinal cognitive, electrophysiological, clinical progression, and biomarker data for over 1,000 European individuals with Mild Cognitive Impairment (MCI). It comprises more than 3,500 electroencephalogram (EEG) recordings and digital cognitive assessment sessions, 1,800 blood samples for dementia risk and progression biomarkers, and nearly 1,000 diagnostic conclusions on dementia progression risk, all collected using harmonised and standardised procedures in Norway, Finland, Italy, and Spain. The multi-national scope of the project ensures diverse European population representation while maintaining rigorous methodological consistency across all participating centres. These data place the project in a unique position to advance our understanding of the interplay between progressing biomarker abnormalities, functional brain changes, and behaviour in MCI and dementia, potentially enabling the development of novel predictive models and intervention strategies.

In this talk, Dr. Ira H. Haraldsen and Dr. Christoffer Hatlestad-Hall present AI-Mind's background and concept, and discuss the project's continuous development and adaptation to the rapidly evolving field of dementia research. They will provide a descriptive overview of the AI-Mind data and some preliminary results encompassing EEG, cognitive, and biomarker measures, highlighting key patterns and relationships that have emerged from the initial analyses. They also discuss lessons learned and perspectives on multi-centre data collection, procedure harmonisation and standardisation, and data quality, including practical challenges encountered during implementation and the solutions developed to address them. Particular attention will be given to the ethical considerations and data governance frameworks that have been essential to the project's success. The talk concludes with a discussion of future directions for clinical studies in dementia in the artificial intelligence era of medical research and practice, exploring how AI-driven approaches may transform early detection, risk stratification, and personalised treatment planning for individuals at risk of dementia.

Disclaimer: The AI-Mind project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964220. This talk reflects the views of the author(s), and the European Commission is not responsible for any use that may be made of the information it contains.